Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)

Next Previous
Trial Profile

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tisagenlecleucel (Primary) ; Corticosteroid; Cyclophosphamide; Doxorubicin; Fludarabine; Lenalidomide; Prednisolone; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LEDA
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 23 Oct 2024 Planned End Date changed from 7 Feb 2029 to 18 Jan 2031.
  • 30 Nov 2023 Planned End Date changed from 21 Jan 2029 to 7 Feb 2029.
  • 30 Nov 2023 Planned primary completion date changed from 6 Jul 2028 to 24 Jul 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top